179 Results for "

Mu-opioid

" in MedChemExpress (MCE) Product Catalog:
Products (179)

179 Results for "Mu-opioid" in MCE Product Catalog:

19
19 Publications Verification
Cat. No.: HY-15122
CAS No.: 115-53-7
Purity:  99.94%
Sinomenine, an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioid receptor .
loading...
    loading...
19
19 Publications Verification
Cat. No.: HY-15122A
CAS No.: 6080-33-7
Purity:  99.89%
Synonyms: Cucoline hydrochloride
Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioid receptor .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-P0210
CAS No.: 78123-71-4
Target:  

Opioid Receptor

Research Areas:  

Cancer

DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-P0210B
CAS No.: 950492-85-0
Target:  

Opioid Receptor

Research Areas:  

Cancer

DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-156131
CAS No.: 53179-11-6
Synonyms: ADL 2-1294
Loperamide (ADL 2-1294) is selective and orally active μ opioid receptor agonist with Ki valuess of 3, 48 and 1156 nM against μ, δ and κ opioid receptor, respectively. Loperamide produces antinociception and antihyperalgesia. Loperamide exhibits peripheral selectivity, enhancing fluid, electrolyte, and glucose absorption, reversing PGE2 (HY-101952)- and Cholera toxin (HY-P1446)-induced intestinal secretion, and reducing intestinal motility. Loperamide can be used for the researches of inflammatory pain and protracted diarrhoea .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-101386
CAS No.: 1997387-43-5
Purity:  99.46%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0185
CAS No.: 189388-22-5
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0185A
CAS No.: 1276123-71-7
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13243
CAS No.: 156053-89-3
Purity:  98.66%
Synonyms: ADL 8-2698; LY 246736
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-A0118A
CAS No.: 1354744-91-4
Synonyms: NKTR-118 oxalate; AZ-13337019 oxalate
Target:  

Opioid Receptor

Research Areas:  

Metabolic Disease

Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-76657A
CAS No.: 170098-38-1
Synonyms: ADL 8-2698 dihydrate; LY 246736 dihydrate
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease Cancer

Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101318
CAS No.: 72786-10-8
Purity:  98.0%
Synonyms: β-FNA hydrochloride
β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine hydrochloride inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine hydrochloride inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine hydrochloride is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335
CAS No.: 103429-32-9
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335A
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19627A
CAS No.: 1345728-04-2
Synonyms: S-297995 tosylate
Target:  

Opioid Receptor

Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120645
CAS No.: 313669-88-4
Purity:  99.90%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ 35S]GTPγS binding in mouse brain membranes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111454
CAS No.: 2134602-45-0
Purity:  98.01%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P0244
CAS No.: 77614-16-5
Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-104006
CAS No.: 1069498-96-9
Purity:  99.12%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1329A
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
loading...
    loading...